Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.

Revive Therapeutics Ltd. CSE: RVV | USA: RVVTF

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Learn more: https://bit.ly/3FAoFmA 

$RVV $RVVTF #Bucillamine #Infectiousdiseases #Covid19 #OmicronVarient #DeltaVariant #ClinicalTrials #FDA #clinicaltrial

4 Life Sciences Companies Hit the Ground Running in 2022

Learn more: https://bit.ly/3ERmV7Y

$RVV $RVVTF #Bucillamine #covid19

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

IRB approval to initiate Phase 2 study for #methamphetamine abuse disorders

Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs

Learn More: https://bit.ly/3KhMEuk

$RVV $RVVTF #psychedelics #psilocybin #microneedle #mentalwellness #clinicalstudy

Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19

Learn more: https://bit.ly/3JNILwR 

$RVV $RVVTF #Bucillamine #Infectiousdiseases #Covid19 #OmicronVarient #DeltaVariant #ClinicalTrials

4 Life Sciences Companies Hit the Ground Running in 2022

Read more: https://bit.ly/3ERmV7Y 

$RVV $RVVTF #Bucillamine #covid19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Learn More: https://bit.ly/3EEZNd5 

$RVV $RVVTF #Bucillamine #Infectiousdiseases #Covid19 #OmicronVarient #DeltaVariant #ClinicalTrials

PCORI Biweekly COVID-19 Scan: Bucillamine - Oral Anti-Inflammatory Drug, Direct-to-consumer Telehealth Platforms (November 25-December 5, 2021)

Learn more: https://bit.ly/3JgFZzX 

#Bucillamine #COVID19

The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19

Read more: https://bit.ly/3yF9CGj

$RVV $RVVTF #COVID19 #Bucillamine

Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Learn more: https://bit.ly/3rzk6FW 

$RVV $RVVTF #Bucillamine #Infectiousdiseases #Covid19 #OmicronVarient #DeltaVariant #ClinicalTrials

Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Read more: https://bit.ly/30ThoQw 

$RVV $RVVTF #Bucillamine #FDA #orphandrugstatus #livertransplant #IRI

RVV

COM:REVIVETHERA

Revive Therapeutics Ltd.

Last Close

0.01

14/02 15:19

Market Cap

3.58M

Beta: -

Volume Today

2K

Avg: -